History of development

Yunnan Alphy Biotech Co., Ltd began its journey to world success in 2007 and for the period of its existence passed a number of important stages of development.


2007 Foundation of the company and the beginning of cooperation with IOCAS (Institute of Oceanology of the Chinese Academy of Sciences). By this time IOCAS Institute has developed and patented its own technology for cultivation of microalgae and obtaining from them natural astaxanthin.

2009 Obtaining the status of a modern high-tech enterprise from the Yunnan Technical Certification Bureau.

2010 Audit and receipt of ISO 9001 Project inclusion in the China National High Technology Development Program and Plan 863.

2011 Getting FAMI-QS

2012 Getting the Kosher certificate

2013 Establishment of a subsidiary company Yunnan Alcom Biotechnology Co., Ltd

Professor John Van Der Meier, from the Pan-American Association of Marine Biotechnology (Canada), holds the position of the chief consultant at Yunnan Alphy Biotech Co., Ltd.

Commission for Development and Reform of Yunnan Province based on the company Yunnan Alphy Biotech Co., Ltd. creates Research Center for the Study of Haematococcus pluvialis.

2014 Getting the HALAL certificate. Audit and receipt of ISO 22000

2015 Opening of the office in Shanghai. Obtaining a PEOP certificate and the right to label products.

Listing of Securities Yunnan Alphy Biotech Co. Ltd. at the National Chinese Stock Exchange and Quotations (NEEQ). (Exchange code: 834118)

2016 Creation of the ASTA research centre for the study of Haematococcus pluvialis and astaxanthin.

Joining the NAXA association. The opening of the office in Kunming. Obtaining a certificate of organic products. Getting the cGMP certificate. Receiving a CNAS certificate of an accredited laboratory.

2017 Obtaining the status of Novel Food in accordance with EU legislation No 258/97.

2018 Opening an office in Switzerland and the launch of the website www.alphyeurope.com

Participation in the exhibition Vitafoods Europe 2018 in Geneva.

Comments are closed.